LEO Science & Tech Hub announced the appointment of Vladimir Morozov, Ph.D., as Senior Director of Bioinformatics. In this position, Morozov will focus on identifying interesting collaborators for LEO, scope out research and acceleration activities, run collaborative projects and guide development towards dermatological use-cases.
Morozov brings over 25 years of experience in business and academia. His work has focused heavily on genomic data design and analysis, with recent emphasis on machine and deep-learning methods.
Prior to joining LEO Science & Tech Hub, Morozov served as a Bioinformatics Solution Architect at Shire, where he built machine-learning methods to optimize antibody activity and worked with wearable technologies to identify digital biomarkers for patients with Parkinson’s disease and Chronic fatigue syndrome (CFS). Prior to that, he served as a Senior Computational Biology Scientist at ALS Therapy Development Institute where he established Next-Generation Sequencing (NGS) and predictive models from patient data. He has also held positions at Dana-Farber Cancer Institute and LION Bioscience, Inc. Morozov earned a Ph.D. in Chemical Enzymology from Moscow State University.
“With so much of our current research focused on developing new methods for biomarker discovery and analysis, Vladimir is truly a natural addition to our team,” Michael Sierra, Vice President of LEO Science & Tech Hub said. “We are excited by the continued growth of our Boston office and will look to Vladimir to help drive the direction of a number of our early-stage projects.”
“LEO Pharma continues to serve as a strong example of how to prioritize innovation in science and technology to improve patient outcomes,” Morozov said. “The Science & Tech Hub’s unique model allows our team to pursue cutting-edge projects with disruptive potential. I look forward to leveraging my background to have a positive impact on the organization.”